Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics develops long-acting antibody therapies and antibody combinations for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A and IL-23, with programs such as SPY001, SPY002 and SPY003 evaluated as monotherapies and pairwise combinations.
Recurring news for Spyre Therapeutics includes clinical updates from the SKYLINE platform trial in ulcerative colitis and the SKYWAY basket trial in rheumatic diseases, financial results and corporate updates, common-stock financing activity, and equity inducement awards under its 2018 Equity Inducement Plan. Company announcements also describe balance-sheet actions, development priorities and data presentations tied to its immune-mediated disease pipeline.
Spyre Therapeutics (SYRE) reported positive 12‑week Part A induction results from the Phase 2 SKYLINE trial of SPY003, its extended half-life anti‑IL‑23 antibody for moderately‑to‑severely active ulcerative colitis.
SPY003 met the primary endpoint with a statistically significant 10.0‑point reduction in Robart’s Histopathology Index (RHI) at Week 12 (p<0.0001), alongside secondary outcomes of 20% clinical remission and 30% endoscopic improvement and a 3.5‑point mean decline in modified Mayo Score. The safety profile was consistent with the IL‑23 class: 43% of patients experienced treatment‑emergent AEs, 11% had severe AEs, 2% had drug‑related AEs, and there were no drug‑related serious AEs, discontinuations, or deaths.
With prior positive data for SPY001 (anti‑α4β7) and SPY002 (anti‑TL1A), Spyre now has clinical proof‑of‑concept for all three inflammatory bowel disease components, supporting enrollment of SKYLINE Part B combination cohorts, with topline induction data expected in 2027.
Spyre Therapeutics (SYRE) granted inducement equity awards to a new non-executive employee, consisting of options to purchase 2,106 common shares and 745 restricted stock units under its 2018 Equity Inducement Plan. The awards were approved on September 1, 2026 in line with Nasdaq Listing Rule 5635(c)(4).
The stock options have a 10-year term and an exercise price of $88.50, equal to Spyre’s September 1, 2026 closing share price. Options vest 25% on the first anniversary of the employee’s start date, with the remaining 75% vesting monthly over the next three years, subject to continuous service. RSUs vest in four equal annual installments on specified quarterly vesting dates following the start date, also contingent on continued service.
Spyre Therapeutics (SYRE)/b) will participate in three investor conferences in September 2026, including events hosted by Citi, Wells Fargo, and Stifel, featuring fireside chats on September 9, 10, and 23.Management will also hold one-on-one investor meetings, with live audio webcasts and replays available on Spyre’s investor events website.
Spyre Therapeutics (NASDAQ: SYRE) reported topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072. The low dose achieved a statistically significant improvement vs placebo on the primary endpoint DAS28-CRP at Week 12 (-1.9 vs -1.3; p<0.05). High-dose SPY072 showed nominally significant benefit on ACR20 (63% vs 43%), while low dose showed nominally significant benefit on ACR50 (38% vs 19%). Both doses reached target drug levels and provided complete suppression of free TL1A through Week 12, indicating full target engagement.
SPY072 was well tolerated, with adverse events in 27% of active vs 36% of placebo patients, mostly mild or moderate; one serious TEAE occurred per arm, none drug-related, and one death occurred on placebo. Spyre said the efficacy magnitude did not meet its internal bar to prioritize SPY072 RA monotherapy, but the data support broader TL1A potential and ongoing trials in PsA, axSpA, ulcerative colitis and hidradenitis suppurativa, with multiple topline readouts expected from late 2026 through 2028.
Spyre Therapeutics (NASDAQ: SYRE) announced the launch of SPY772, a long-acting combination program pairing SPY072, an anti‑TL1A antibody, with SPY007, a novel anti‑IL‑17A/F antibody, for Hidradenitis Suppurativa (HS).
The company also initiated SKYLIGHT, a randomized, placebo-controlled Phase 2 proof‑of‑concept trial in approximately 150 adults with moderate‑to‑severe HS. All participants will receive background bimekizumab, plus either SPY072 or placebo. The primary endpoint is Week 16 HiSCR75 response, with topline data planned for late 2027 or early 2028. According to Spyre Therapeutics, positive SKYLIGHT data could support advancement of the long‑acting SPY772 coformulation in HS and exploration of additional indications.
Spyre Therapeutics (NASDAQ: SYRE) granted equity inducement awards to four non-executive employees under its 2018 Equity Inducement Plan. The independent Compensation Committee approved stock options for an aggregate 19,436 shares and 6,186 RSUs on August 3, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and an exercise price of $94.93, equal to Spyre’s August 3, 2026 closing share price. Options vest 25% on the first employment anniversary and monthly thereafter over four years, while RSUs vest in four equal annual installments on specified quarterly dates, in each case subject to continued service.
Spyre Therapeutics (NASDAQ: SYRE) reported second quarter 2026 results and clinical progress, highlighted by positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE ulcerative colitis trial, which achieved primary histologic endpoints with statistically significant Robart’s Histopathology Index reductions and clinically meaningful remission and endoscopic improvement rates.
The company completed enrollment in all three sub-studies of the Phase 2 SKYWAY basket trial of anti-TL1A antibody SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with proof-of-concept data expected from September through fourth quarter 2026. Spyre reported $1.1453 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, supported by $435.2 million in net proceeds from an April equity offering, and projects cash runway into the second half of 2029. R&D expenses rose to $65.5 million, G&A to $16.1 million, and net loss was $36.2 million for the quarter.
Spyre Therapeutics (NASDAQ: SYRE) granted equity inducement awards to six non-executive employees under its 2018 Equity Inducement Plan.
The awards include stock options for 58,843 shares at an exercise price of $88.89 with a 10-year term, plus 2,134 RSUs, all subject to multi-year vesting and continued service.
Spyre Therapeutics (NASDAQ: SYRE) reported positive 12-week Part A induction data from the Phase 2 SKYLINE trial of SPY002 in moderate-to-severe ulcerative colitis. SPY002 met the primary endpoint with a 10.7-point RHI reduction (p<0.0001), plus 33% clinical remission, 42% endoscopic improvement, and -3.7 modified Mayo Score, with no drug-related serious adverse events.
Spyre Therapeutics (NASDAQ: SYRE) granted stock options to purchase an aggregate of 51,300 shares of common stock to four non-executive employees as equity inducement awards under its 2018 Equity Inducement Plan.
The options have a 10-year term, a $70.54 exercise price, and a time-based vesting schedule tied to continued service.